Background. Transition from intravenous (IV) to oral (PO) antibiotics is common practice in patients with Gram-positive bloodstream infections (GP-BSI); however, clinical data evaluating IV to PO switch options are lacking. The objective of this study was to examine effectiveness of PO antibiotics for definitive treatment of GP-BSI, with a focus on bioavailability (BA).

Methods. This was a single-center, retrospective cohort study of adult inpatients admitted to an 874-bed academic medical center in Charlotte, NC between September 1, 2014 and August 31, 2017. Patients with a GP-BSI who received appropriate antibiotic therapy with at least one third of their total course administered PO were included. Patients with GP-BSI caused by staphylococcal species were excluded. The primary endpoint was clinical failure in patients receiving high (≥90%) or low (<90%) BA agents. Secondary endpoints included clinical failure stratified by antibiotic group, bactericidal vs. bacteriostatic agents, and organism. Chi-square and Fisher’s exact tests were used to examine clinical failure.

Results. Of the 1,034 patients included, 261 were receiving high BA agents, and 772 were receiving low BA agents. The median age was 58, 51% were women, 74.8% of patients had streptococcal bacteremia (26.2% S. pneumoniae), with pulmonary being the most common source (30.1%). There were no major differences in baseline demographic and clinical characteristics between groups. The median treatment duration with IV antibiotics was 4 and 5 days in the high and low BA groups, respectively (P = 0.12). There was no statistically significant difference in clinical failure in the high vs. low BA groups (19% vs. 23%, P = 0.66, respectively). Clinical failure stratified by antibiotic group, bacteriostatic vs. bactericidal agent (OR 1.43, CI 0.26–7.90), and organism also did not yield statistically significant differences.

Conclusion. These data demonstrate similar rates of clinical failure among patients definitively treated with high or low BA agents for GP-BSI. High BA agents such as fluoroquinolones may not be needed for all patients with GP-BSI, where more targeted β-lactam therapy may be appropriate. Additional prospective studies with larger sample sizes are needed to further validate these conclusions.

Disclosures. All authors: No reported disclosures.

1011. Sepsis and Secondary Hemophagocytic Lymphohistiocytosis
Farhan Fazal, MBBS, MD,1 Navnet Vig, MD,2 Manish Soneja, MD Medicine1
Dipendra K. Mitra, MD,1 Sk. Panda, MD,2 Gita Satpathy, MD,2 Naval Kishore Vikram, MD,1 RM Pandey, MD2 and PK. Chaturvedi, MD,2 Medicine, All India Institute of Medical Science (AIIMS), New Delhi, India, “All India Institute of Medical Science (AIIMS), New Delhi, India

Session: 131. Bacteremia and Endocarditis
Friday, October 5, 2018: 12:30 PM

Background. Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory condition diagnosed by HLH 2004 criteria. This criterion has common clinical and laboratory features with sepsis and tropical fevers, but there is marked difference in management and outcome of these two entities. The study is conducted to know whether there is any difference in the clinical, laboratory features, management, and outcome of sepsis with or without secondary HLH.

Methods. This is a prospective observational study where patients presenting with sepsis and bicytopenia are included. The patients underwent relevant investigations according to 2004 HLH diagnostic criteria. The patients are divided into sepsis with or without HLH. The underlying etiology, treatment, and outcome of the two groups are analysed.

Results. Fifty sepsis patients are included in the study, out of which 28 fulfilled the HLH diagnostic criteria which comprised of 18 men and 10 women. The etiology were underlying etiology alone without immunosuppressive treatment was given in 39%. The supportive treatment was given to 53% and etoposide was added in 7%. Treatment for fulfilling in both groups is given in Figure 1, showing an increased occurrence of spleno.

Conclusion. These data demonstrate similar rates of clinical failure among patients definitively treated with high or low BA agents for GP-BSI. High BA agents such as fluoroquinolones may not be needed for all patients with GP-BSI, where more targeted β-lactam therapy may be appropriate. Additional prospective studies with larger sample sizes are needed to further validate these conclusions.

Disclosures. All authors: No reported disclosures.

1012. Group B Streptococcus Bacteremia in Non-Pregnant Adults in a Tertiary Care Hospital Between 2008 and 2017 in Korea
Jeong Sun Lee, MD; Sun Hee Lee, MD, PhD; Shinwon Lee, MD; Rye-Hyung Kim, MD; Kang Young Kim, MD and Youngri Park, MD

Session: 131. Bacteremia and Endocarditis
Friday, October 5, 2018: 12:30 PM

Background. Group B streptococcus (GBS) has emerged as an important cause of invasive infection in nonpregnant adults. This study aimed to describe the clinical characteristics and risk factors associated with GBS bacteremia in nonpregnant adult patients in Korea.

Methods. Our retrospective study reviews the hospital records of nonpregnant adults, aged ≥18 years, with GBS bacteremia who attended the Pusan National University Hospital between January 1, 2008 and December 31, 2017. The presence of underlying diseases, such as cardiovascular diseases, diabetes mellitus, malignancy, liver disease and/or alcohol abuse and renal disease, as well as possible portals of entry of infection, was analyzed.

Results. During the period of 10 years, there were 79 patients with GBS bacteremia. In 47 episodes (59.5%), patients were aged 60 years or older and 43 (54.4%) episodes occurred in females. Their mean age was 61 years (range, 19–91 years) and 70 patients (88.6%) had underlying diseases. Cardiovascular diseases (n = 35, 44.3%) were the most common underlying conditions, and diabetes mellitus (n = 27, 34.2%) and nonhematologic malignancy (n = 27, 34.2%) were second. Germinocytic cancer composed nearly half of nonhematologic malignancy (n = 13, 48.1%). The other comorbid conditions were liver disease and/or alcohol abuse (n = 14, 17.7%), renal disease (n = 13, 16.5%) and hematologic malignancy (n = 7, 8.9%). The most common clinical syndrome was primary bacteremia (n = 31, 39.2%). The others were bone and joint infection (n = 15, 19.0%), urinary tract infection (n = 12, 15.2%), skin and soft-tissue infection (n = 7, 8.9%), infective endocarditis (n = 4, 5.1%), peritonitis (n = 4, 5.1%), and meningitis (n = 2, 2.5%). The overall mortality rate was 13.9%, all patients had at least one underlying disease. The mortality rate of primary bacteremia was significantly higher than those of bacteremia with focus (29.0% vs. 4.2%, respectively; P = 0.002). Hematologic malignancy, liver disease, and/or alcohol abuse and renal disease were significantly associated with the primary bacteremia.

Conclusion. GBS bacteremia is a significant problem in nonpregnant patients, especially primary bacteremia resulted in a high rate of mortality (29%). Hematologic malignancy, liver disease, and/or alcohol abuse and renal disease were significantly related to primary bacteremia occurrence.

Disclosures. All authors: No reported disclosures.

1013. If Blood Cultures Were Not Done Before Starting Antibiotics, Is It Of Any Value to Obtain Them Later?
Kenneth Rand, MD; Stacy Reel, MD; Brandon Allen, MD; Thomas Payton, MD; George Lepori, MT, MBA and Kimberly Rivera, MD; Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, “Department of Pathology, University of Florida, Gainesville, Florida, “University of Florida, Gainesville, Florida, “Emergency Medicine, University of Florida, Gainesville, Florida

Session: 131. Bacteremia and Endocarditis
Friday, October 5, 2018: 12:30 PM

Background. Obtaining blood cultures before starting antibiotics is one of the pillars of the Surviving Sepsis Campaign (SSC), and delay in obtaining blood cultures (BC) after starting antibiotics is associated with increased mortality (Levy M 2015, Prunelli L 2018), but we were unable to find data on the relationship between such a delay and a reduction in percentage of positive cultures.

Methods. All adult patients (>18) admitted to the UFHealth Shands Emergency Department (ED) between August 2012 and December 2016 were included in the study (N = 30,743), excluding hospital-hospital transfers. BC were done with BacTec aerobic, anaerobic, and pediatric resin bottles, incubated for 5 days. We calculated the hourly rate of positive BC obtained before and after the start of IV antibiotics by subtracting the time stamp in the electronic medical record (Epic) between the first
Disclosures. All authors: No reported disclosures.

1014. Microbiology and Outcome of Bloodstream Infections in Children With Intestinal Failure
Talal Sedidk, MD; Yvonne Maldonado, MD, FIDSA, FPIDS; Colleen Nespor, RN, CNS; John Kerner, MD; and Hayley Cans, MD, FPIDS; Pediatrics, Stanford University School of Medicine, Stanford, California, 1Pediatrics, Stanford Health Care, Stanford, California, 2Session: 131. Bacteremia and Endocarditis
Friday, October 5, 2018: 12:30 PM

Background. Children with intestinal failure (IF) represent 20% of bloodstream infection (BSI) pediatric hospitalizations. We studied the microbiology and associated outcomes of this population.

Methods. Retrospective cohort study of children ≤18 years with IF dependent on parenteral nutrition (PN), with ≥1 BSI from January 2007 to December 2016. Organisms causing BSIs were divided into skin or GI bacteria and fungi based on human habitat and kingdom. The impact of ethanol lock therapy (ELT) and clinical outcomes of this population.

Results. There were 254 BSIs in 54 children resulting from GI bacteria (58%), skin organisms (18%), and fungi (24%). The proportion of skin bacteria was greater when tested on ELT (27% off of vs. 45% on ELT; P = 0.003), while the proportion of GI bacteria was lower (67% off of vs. 52% on ELT; P = 0.018). Significantly more fungal BSIs were seen in older children: mean age 4.2 years (95% CI: 2.9–5.5) vs. 2.7 years (95% CI: 2.3–3) with other organisms; P = 0.014. Fungal BSIs were more common in SIBO (18% vs. 5% with and without SIBO; P = 0.013). Twenty-eight organisms were resistant to cefazidine, and five to cefepime. Hospitalization days totaled 2,432.

Conclusion. The majority BSIs in children resulted from GI bacteria, suggesting intestinal translocation; these infections were not less common in older children despite increased intestinal mass, signifying continued translocation. BSI with GI bacteria was not more common in children with SIBO despite increased intestinal bacterial load, possibly due to antibiotic suppressive therapy, which instead lead to more fungal BSIs. Prevention of BSI by ELT was less effective for skin bacteria which were resistant to ceftazidime, and five to cefepime. Hospitalization days totaled 2,432.

1016. Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) With Fever and Neutropenia (FN): Predictors for Morbidity and Mortality
Alison G. Freifeld, MD; Andrea Zimmer, MD; Christopher Arnold, MD; John W. Baddley, MD; Pranatharthi Chandrasekaran, MD; Zeinab El Boghdady, MBBS; Eileen K. Maziarz, MD; Jose G. Montoya, MD, FIDSA; Steven Pergam, MD, MPH, FIDSA; Kenneth Y. Rolston, MD; Gower Sayanarayana, MD; Shiona Shosham, MD; Lynne Strasfeld, MD; Randy Taplitz, MD; Jane Meza, PhD; Jo-Anne Young, MD; Yuning Zhang, PhD and Kenneth V. Shoham, MD, PhD; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, 1UNMC, Omaha, Nebraska, 2Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, 3University of Alabama at Birmingham, Birmingham, Alabama, 4Infectious Diseases, Wayne State University, Detroit, Michigan, 5Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, Ohio, 6Division of Infectious Disease and Internal Medicine, University of Miami, Miami, Florida, 7Division of Infectious Diseases, North Carolina, 8Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, 9Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, 10Division of Infectious Diseases and Medical Microbiology, University of Washington, Seattle, Washington, 11Department of Infectious Disease Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, 12Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, 13Washington Hospital Center, Washington, DC, 14Division of Infectious Disease, Oregon Health & Science University, Portland, Oregon, 15Division of Infectious Diseases, University of California San Diego Health Centers, San Diego, California, 16Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine of Cornell University, New York, New York, 17University of Minnesota, Minneapolis, Minnesota, 18University of Nebraska Medical Center, Omaha, Nebraska, 19Session: 131. Bacteremia and Endocarditis
Friday, October 5, 2018: 12:30 PM

Background. Bloodstream infection (BSI) during neutropenia is associated with high risk for morbidity and mortality in patients with hematologic malignancies receiving chemotherapy or undergoing hematopoietic cell transplant (HCT). We sought to identify factors associated with increased risk for critical illness (CI) morbidity and mortality within 7 days of BSI by index FN following chemotherapy.

Methods. A prospective ongoing survey among 14 high-volume US cancer centers submitting clinical and microbiologic data from consecutive HM patients with blood stream infection (BSI) during first FN after cytotoxic chemotherapy or HCT. We evaluated factors influencing poor outcomes defined as critical illness (need for pressor support, mechanical ventilation, new pneumonia or new BSI) within 7 days of BSI with index FN. Concordance between antibiotic and BSI isolate was determined by investigator (AZ, AF) interpretation of susceptibility reports provided by each center compared with the initial antimicrobial regimen (IAR) used, for single organism bacteremias only.

Results. Among 294 FN bacteremic episodes (93 HCT) were 336 bacterial pathogens (48.5% Gram-negative [GN], 46.5% Gram-positive [GP], and 6% anaerobes). Death occurred in 112/294 (4%) and 41/294 (14%) had CI by day 8. At FN presentation,